13 January 2021

Moderna has announced that Swissmedic, the Swiss Agency for Therapeutic Products, has authorised the use of Moderna’s mRNA-1273 vaccine in Switzerland. The temporary approval was based on the regulator’s ordinary approvals procedure and a rolling submission of data and scientific evidence from Moderna’s its pivotal Phase III clinical study.

Regeneron, the US Department of Health and Human Services (HHS) and the US Department of Defence (DOD) have entered into a purchase agreement. According to the agreement, Regeneron will supply casirivimab and imdevimab antibody cocktail doses for use in non-hospitalized Covid-19 patients to HHS and DODas part of the US Government’s Operation Warp Speed goals.

Sinovac has partnered with Malaysian pharma company Pharmaniaga to supply 14 million doses of the former’s inactivated Covid-19 vaccines to Malaysia. Pharmaniaga reported that the vaccines will be made available to the Malaysian public by the end of March 2021.

South Korea based biopharma Celltrion confirmed the efficacy of Regkirona, also known as CT-P59, its Covid-19 antibody therapeutic treatment in Phase II clinical trials. According to Kwon Ki-sung, the head of Celltrion’s research and development unit, Regkirona showed better therapeutic effective than other antibody treatments in the study, such as those developed by Eli Lilly and Regeneron.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.